Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06334757
Status:
RECRUITING
Last Update Posted:
2024-03-28
First Post:
2024-03-21
Brief Title:
Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
Sponsor:
Henan Cancer Hospital
Organization:
Henan Cancer Hospital
Organization Data
Organization:
Henan Cancer Hospital
Class:
OTHER_GOV
Study ID:
HLX10IIT22
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Henan Cancer Hospital
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None